As AI continues to reshape business models and workflows, the true differentiator will be human ingenuity and innovations ...

Melissa Sarnowski has been a game writer for over two years. While she's willing to dig into any game for an article, she heavily focuses on The Legend of Zelda, Resident Evil, Final Fantasy, and The ...

Arrhythmias, or irregular heart rhythms, are common complications of HCM. The thickened heart muscle disrupts the electrical pathways that coordinate heartbeat, leading to arrhythmias. Atrial ...

FPC is known for its expertise in payroll reconstruction, agency notice resolution, Employee Retention Credit (ERC) filings, and merger & acquisition compliance. By integrating FPC’s capabilities, HCM ...

MINNEAPOLIS — Readouts of data on an experimental drug for hypertrophic cardiomyopathies showed the agent appeared safe and effective in long-term treatment and can significantly improve exercise ...

Oracle yesterday announced more than a dozen AI agents that will be available as part of its Fusion HCM application, complementing the twelve already announced earlier this year, along with many ...

AUSTIN, Texas, Sept. 16, 2025 /PRNewswire/ -- Oracle has been named a Leader in the 2025 Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for Oracle Fusion Cloud Human ...

Oracle Corp. today announced a series of new agentic artificial intelligence extensions to its Fusion Cloud Human Capital Management suite, bringing the number of agents in the application to more ...

MADRID, Spain—For patients with hypertrophic cardiomyopathy (HCM), research presented today at the European Society of Cardiology (ESC) Congress 2025 demonstrated both the promise and the potential ...

Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...

Mavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain. We conducted a phase 3, ...